Exposure Therapy for Adults with Mani Allergy
Peanut Allergy Exposure Therapy Shows Promise for Adults
Table of Contents
LONDON (HealthDay News) — A recent clinical trial indicates that adults with peanut allergies can be safely treated with exposure therapy to build resistance. The study, published in Allergy magazine, revealed that 67% of participants developed the ability to tolerate at least five peanuts without experiencing an allergic reaction.
Adults Benefit from Oral immunotherapy
researchers highlight that this study marks one of the first to assess exposure therapy, also known as oral immunotherapy (OIT), in adults. This type of treatment typically is administered to children,whose immune systems are still developing.
Exposure therapy involves patients consuming small, gradually increasing doses of their specific food allergen daily to increase their tolerance.
Quality of Life Improvement
“the constant fear of possibly life-threatening reactions places a notable burden on individuals with peanut allergies,” said stephen Till, a professor of allergy at King’s Collage London, in a press release. “Currently, the primary management strategy involves strict avoidance and treatment of allergic reactions, frequently enough requiring epinephrine.”
Till noted that while peanut immunotherapy has demonstrated effectiveness in children, this trial offers preliminary evidence suggesting that adults can also benefit, leading to an improved quality of life.
According to Till, the average tolerated peanut dose increased 100-fold during the trial.
Trial Details
The clinical trial involved 21 adults, aged 18 to 40, with diagnosed peanut allergies.Participants received daily doses of peanut flour mixed into their food.
The trial’s objective was for patients to reach a daily dose of 1 gram of peanut flour without any adverse reaction for a minimum of four weeks. Later, participants were challenged with either a dose of peanuts or a placebo.
Following the challenge,patients continued the daily dose for at least three more months.
“We are very pleased with these results,” Till stated. “The effectiveness rate aligns well with oral immunotherapy trials involving peanuts in children.”
Future Research
Future research will focus on confirming these findings in larger trials. Investigators also aim to identify adult patients who are most likely to benefit from oral immunotherapy and to determine if long-term tolerance can be achieved in this age group.
Impact on Daily Life
Hannah Hunter, a dietitian specializing in allergies at Guy’s and St Thomas’ NHS Foundation Trust, emphasized the daily anxieties faced by those with peanut allergies.”People with peanut allergies live with the constant fear that somthing they eat has inadvertently exposed to the peanut,” Hunter said.
“Everyday situations, such as eating in restaurants and social events, cause anxiety, and our patients tell us that the condition also affects travel and career options,” Hunter added.
hunter noted a significant improvement in quality of life and a reduction in food-related anxiety following oral immunotherapy. “Many participants who completed the trial reported that the treatment had transformed their lives, allowing them to live without fear.”
Participant Testimony
chris,a 28-year-old participant who had been allergic to peanuts since infancy,shared his experience. “I am very proud to have been part of this trial and very happy to say that I used to be allergic to the peanuts, but thanks to this trial, this is no longer a concern,” Chris said. “My family and I were always anxious that even a trail of peanuts could endanger life.”
Chris described the trial as “an captivating experience,” noting that he had always “associated the flavor and smell of peanuts with fear and death.” He began by ingesting a small amount of peanut flour with yogurt and eventually could eat four peanuts at onc.
“Now,I take four peanuts every day with my breakfast to maintain my immunity,” he said.
“before, a small mistake could have potentially mortal impacts, but now I am not afraid to collapse and die for eating food to carry,” Chris concluded.
More Information
The Children’s Hospital of Philadelphia provides additional information on exposure therapy for food allergies.
Peanut Allergy Exposure Therapy: Your Questions Answered
Are you or a loved one navigating the challenges of a peanut allergy? This article delves into a recent study on exposure therapy for adults with peanut allergies, providing clarity and insights into this promising treatment. We’ll explore the findings, address common questions, and highlight the impact on daily life.
What is Peanut Allergy Exposure Therapy?
Q: What is peanut allergy exposure therapy?
A: Peanut allergy exposure therapy, also known as oral immunotherapy (OIT), involves gradually introducing small, increasing doses of peanut into the diet of a person with a peanut allergy. The goal is to desensitize the immune system and build tolerance to peanuts, reducing the risk of a severe allergic reaction.
The Recent Study: Key Findings
Q: What did the recent study on adult peanut allergy exposure therapy reveal?
A: A recent clinical trial showed promising results for adults with peanut allergies. The study demonstrated that:
- 67% of participants developed the ability to tolerate at least five peanuts without experiencing an allergic reaction.
- The average tolerated peanut dose increased considerably during the trial.
Q: Who was involved in the study?
A: The trial involved 21 adults, aged 18 to 40, who had been diagnosed with peanut allergies.
Q: How did the participants undergo treatment?
A: Participants received daily doses of peanut flour mixed into their food. The objective was to reach a daily dose of 1 gram of peanut flour without adverse reactions for a minimum of four weeks. Following this, participants were challenged with either a dose of peanuts or a placebo and continued the daily dose for at least three more months.
Benefits and Impact
Q: What are the potential benefits of peanut allergy exposure therapy?
A: This therapy can significantly improve the quality of life. It reduces the constant fear of accidental exposure and subsequent reactions. The ability to tolerate peanuts can decrease the anxiety associated with social events, dining out, travel, and career choices.
Q: How does this compare to existing treatments?
A: Currently, the primary management strategy for peanut allergies is strict avoidance of peanuts and treatment of allergic reactions, wich may involve epinephrine. This study offers preliminary evidence that oral immunotherapy can be an effective additional method to improve quality of life.
Expert Perspectives
Q: What do experts say about these findings?
A:Stephen Till, a professor of allergy at King’s College London, noted, ”We are very pleased with these results,” and that “The effectiveness rate aligns well with oral immunotherapy trials involving peanuts in children.” He also noted the notable burden on individuals with peanut allergies and the potential for improved quality of life.
Hannah Hunter, a dietitian specializing in allergies, emphasized the daily anxieties faced by those with peanut allergies and highlighted that many participants reported the treatment transformed their lives, by removing fear.
Personal Experiences
Q: What does a participant’s experience reveal?
A: Chris, a 28-year-old participant who had been allergic as infancy, shared that the trial was captivating. Chris,who initially associated the smell of peanuts with fear and death,could eventually eat four peanuts daily to maintain immunity. The trial transformed his life,removing the constant fear associated with the possibility of a life-threatening reaction from accidental peanut exposure.
Future Research
Q: what’s next for peanut allergy exposure therapy research?
A: Future research will focus on confirming these findings in larger trials. Investigators also aim to identify which adult patients are most likely to benefit and determine if long-term tolerance can be achieved.
Additional resources
Q: Where can I find more information?
A: The Children’s Hospital of Philadelphia provides additional information on exposure therapy for food allergies.